Indeed, based on the study findings, we could advance the potential role of AhR/N-cadherin as a prognostic marker, being able to suggest a more aggressive phenotype in thyroid carcinoma as evidenced by the high levels of AhR/N-cadherin found in most patients of the PTC-A and PDTC/ATC groups. The gene discussed is AHR; the disease is thyroid gland carcinoma.